Luzu is owned by Bausch.
Luzu contains Luliconazole.
Luzu has a total of 4 drug patents out of which 0 drug patents have expired.
Luzu was authorised for market use on 14 November, 2013.
Luzu is available in cream;topical dosage forms.
Luzu can be used as treatment of fungal infections.
The generics of Luzu are possible to be released after 28 April, 2034.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9199977 | BAUSCH | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
Sep, 2033
(10 years from now) | |
US9012484 | BAUSCH | Crystal and pharmaceutical preparation containing the same crystal |
Sep, 2033
(10 years from now) | |
US9453006 | BAUSCH | Crystalline form having specific crystal habit and pharmaceutical composition containing this crystalline form as active ingredient |
Sep, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8980931 | BAUSCH | Method of evaluating pharmaceutical preparation containing luliconazole and index substance |
Apr, 2034
(11 years from now) |
Drugs and Companies using LULICONAZOLE ingredient
Market Authorisation Date: 14 November, 2013
Treatment: Treatment of fungal infections
Dosage: CREAM;TOPICAL
12
Japan
3
United States
3
China
3
European Union
2
Russia
2
India
1
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic